. 2017 May 16;14(5):e1002299. doi: 10.1371/journal.pmed.1002299

Table 3. Hazard ratios and incidence rate ratios.

Time point	Measure	CQ versus CQ+PQ^a	AL versus AL+PQ^a	AL versus CQ	AL+PQ versus CQ+PQ
Day 28	Hazard ratio	—, p = 0.0001	5.1 (1.1–23.5), p = 0.034	2.9 (0.9–9.0), p = 0.07	—, p = 0.08
Day 42	Hazard ratio	18.5 (2.5–138.5), p = 0.005	5.9 (2.3–15.3), p < 0.001	1.8 (1.0–3.2), p = 0.059	5.4 (0.6–46.6), p = 0.122
End of follow-up	Hazard ratio	5.4 (3.0–9.7), p < 0.001	5.2 (3.0–9.0), p < 0.001	1.3 (0.9–1.9), p = 0.127	1.3 (0.6–2.6), p = 0.523
End of follow-up	Incidence rate ratio	5.1 (2.9–9.1), p < 0.001	6.4 (3.6–11.3), p < 0.001	0.9 (0.6–1.4), p = 0.530	1.1 (0.5–1.9), p = 0.964

Hazard ratios (95% CIs) calculated from Cox regression. Incidence rate ratios (95% CIs) calculated at the end of follow-up.

^aExcluding patients not randomized to PQ versus no PQ.

AL, artemether-lumefantrine; AL+PQ, artemether-lumefantrine + primaquine; CQ, chloroquine; CQ+PQ, chloroquine + primaquine.